search

Active clinical trials for "Arthritis, Juvenile"

Results 201-210 of 274

Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)

Juvenile Idiopathic Arthritis

Phase 1 study to describe pharmacokinetics of CP-690,550 in pediatric patients 2 to less than 18 years of age with Juvenile Idiopathic Rheumatoid Arthritis (JIA).

Completed17 enrollment criteria

Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

Juvenile Idiopathic Arthritis

This is an assessment of Pharmacokinetics of a single oral dose of VIMOVO in healthy adult volunteers.

Completed6 enrollment criteria

Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody...

Systemic Juvenile Idiopathic ArthritisPeriodic Fever Syndrome

This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-1β Humanized Monoclonal Antibody injection in Healthy Subjects. Pharmacokinetics, Pharmacodynamics and Anti-drug antibody (ADA) data will be collected; Drug safety, tolerability and immunogenicity for healthy subjects will be evaluated.

Unknown status28 enrollment criteria

Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

A randomized double blind clinical trial to assess efficacy of leflunomide in treatment of refractory juvenile idiopathic arthritis. Patients are randomly divided into two groups. In group 1 leflunomide and in group 2 placebos will be added to conventional treatment for three months. therapeutic responses will be evaluated by ACRpedi (American College of Rheumatology Pediatric) scores every 4 weeks.

Unknown status11 enrollment criteria

Efficacy and Safety of Tocilizumab in Adult's Still Disease

Adult's Still Disease

Patients with adult's Still disease suffer from acute inflammatory symptoms such as fever, arthritis, rash, and acute phase response often requiring high dose corticosteroids. In view of several case reports which have shown dramatic improvement in patients treated with Tocilizumab and a phase 2 study of this drug in children with Still's disease, the objective of the current study is to assess the efficacy and safety of Tocilizumab in patients with adult's Still disease.

Unknown status22 enrollment criteria

Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis...

ArthritisJuvenile Rheumatoid

This multi-center observational Registry will collect long-term safety data on patients treated with celecoxib or non-selective nonsteroidal anti-inflammatory drugs (nsNSAIDs) as used in clinical practice for the treatment of Juvenile Idiopathic Arthritis (JIA).

Terminated5 enrollment criteria

Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis

Juvenile Idiopathic ArthritisPain

The primary objectives of the proposed pilot randomized controlled trial (RCT) will be to examine: (1) the feasibility of a full RCT to evaluate the effectiveness of two popular types of physical activity (PA), a yoga training program and an aerobic dance training program, in female adolescents (13 to 18 years old) with juvenile idiopathic arthritis (JIA) compared to a wait list control group; and (2) the acceptability of these interventions. A three-arm prospective randomized open-label study with a parallel group design will be used. A total of 25 in a ratio of 2:2:1 female adolescents with JIA who have pain will be randomized to one of the three groups: 1) online yoga training program (Group A) (n=10), 2) online aerobic dance training program (Group B) (n=10) and 3) waiting list control group (Group C) (n=5). Participants in groups A and B will complete three individual 1-hour sessions per week using online exercise videos, as well as one 1-hour virtual group session per week using a video-conferencing platform (GoToMeeting) for 12 weeks. These participants will also take part in weekly e-consultations with a research coordinator and discussions on Facebook with other participants. Participants from all groups will be given access to an electronic educational pamphlet on PA for arthritis developed by The Arthritis Society to review via an online platform. Feasibility, acceptability and usability of Facebook and GoToMeeting will be assessed at the end of the program. Pain intensity (Primary outcome), participation in general physical activity, morning stiffness, functional status, fatigue, self-efficacy and patient global assessment will be assessed using self-administered electronic surveys at baseline, weekly until the end of the 12 weeks program.

Unknown status17 enrollment criteria

Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

The aim of this study is to explore if an already established diet with anti-inflammatory effect in paediatric inflammatory bowel disease would have an anti-inflammatory effect in children with JIA. The diet is called specific carbohydrate diet.

Unknown status9 enrollment criteria

The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated...

UveitisArthritis1 more

This study will investigate the safety and effectiveness of the drug Enbrel (TNFR:Fc) to treat uveitis (eye inflammation) in patients with juvenile rheumatoid arthritis.

Unknown status17 enrollment criteria

Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

The purpose of this study is to determine whether etanercept can be withdrawn successfully (i.e. no occurrence of flares) in juvenile idiopathic arthritis (JIA) patients in whom disease remission is reached. Goals: to investigate in a randomized controlled trial: which proportion of JIA patients in remission can successfully discontinue etanercept compared to JIA patients in remission who continue etanercept; if time in remission on etanercept is an important factor in retaining remission after discontinuation of etanercept. to investigate in alle JIA patients who discontinue etanercept (including the control group): predicting factors (patient or disease characteristics, including time in remission, and MRP8/MRP14) for successfully discontinuation of etanercept; the disease course after discontinuation of etanercept (time to flare) and the effect of restarting etanercept after flaring.

Unknown status10 enrollment criteria
1...202122...28

Need Help? Contact our team!


We'll reach out to this number within 24 hrs